Soyka Michael, Kranzler Henry R, Berglund Mats, Gorelick David, Hesselbrock Victor, Johnson Bankole A, Möller Hans-Jürgen
Psychiatric Hospital Meiringen, Meiringen, Switzerland.
World J Biol Psychiatry. 2008;9(1):6-23. doi: 10.1080/15622970801896390.
These practice guidelines for the biological treatment of substance use disorders were developed by an international Task Force of the World Federation of Societies of Biological Psychiatry (WFSBP). The goal during the development of these guidelines was to review systematically all available evidence pertaining to the treatment of substance use disorders, and to reach a consensus on a series of practice recommendations that are clinically and scientifically meaningful based on the available evidence. These guidelines are intended for use by physicians evaluating and treating people with substance use disorders and are primarily concerned with the biological treatment of adults suffering from substance use disorders. The data used to develop these guidelines were extracted primarily from various national treatment guidelines for substance use disorders, as well as from meta-analyses, reviews and randomized clinical trials on the efficacy of pharmacological and other biological treatment interventions identified by a search of the MEDLINE database and Cochrane Library. The identified literature was evaluated with respect to the strength of evidence for its efficacy and then categorized into four levels of evidence (A-D). This first part of the guidelines covers the treatment of alcohol dependence; Part 2 will be devoted to the treatment of drug dependence.
这些物质使用障碍生物治疗实践指南由世界生物精神病学协会联合会（WFSBP）的一个国际特别工作组制定。制定这些指南的目的是系统回顾与物质使用障碍治疗相关的所有现有证据，并基于现有证据就一系列具有临床和科学意义的实践建议达成共识。这些指南供评估和治疗物质使用障碍患者的医生使用，主要关注患有物质使用障碍的成年人的生物治疗。用于制定这些指南的数据主要从各种国家物质使用障碍治疗指南中提取，以及通过检索MEDLINE数据库和Cochrane图书馆确定的关于药物和其他生物治疗干预疗效的荟萃分析、综述和随机临床试验中提取。对所识别的文献就其疗效证据的强度进行评估，然后分为四个证据级别（A - D）。本指南的第一部分涵盖酒精依赖的治疗；第二部分将专门讨论药物依赖的治疗。
